OncoTherapy Science
4564.TTSE GROWTHPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥809m | ¥750m | ¥610m | ¥1.1bn | ¥1.2bn | ¥332m |
| Operating income | −¥810m | −¥798m | −¥1.1bn | −¥1.1bn | −¥2.1bn | −¥1.6bn |
| Ordinary income | −¥846m | −¥815m | −¥1.1bn | −¥1.1bn | −¥2.1bn | −¥1.6bn |
| Net income (owners) | −¥911m | −¥815m | −¥1.3bn | −¥1.1bn | −¥2.6bn | −¥1.6bn |
| Total assets | ¥2.4bn | ¥1.2bn | ¥867m | ¥1.5bn | ¥2.7bn | ¥3.4bn |
| Net assets / equity | ¥2.1bn | ¥729m | ¥354m | ¥855m | ¥2.0bn | ¥3.1bn |
| Operating cash flow | −¥923m | −¥815m | −¥1.2bn | −¥795m | −¥2.1bn | −¥1.8bn |
| EPS (basic) | ¥-2.77 | ¥-3.12 | ¥-6.05 | ¥-5.81 | ¥-13.72 | ¥-8.86 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 174 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Cancer Precision Medical Business | ¥806m | −¥56m |
| Research And Development Of Pharmaceutical Products | ¥2m | −¥532m |
| Adjustments & eliminations | — | −¥223m |
| Total | ¥809m | −¥587m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.